DexCom Inc. Stock Underperforms Wednesday When Compared To Competitors

GT Biopharma Inc

Change company Symbol lookup

Select an option...

GTBP GT Biopharma Inc

UNH UnitedHealth Group Inc

BAC Bank of America Corp

WSO Watsco Inc

LITB LightInTheBox Holding Co Ltd

CVCY Central Valley Community Bancorp

AFAQU AF Acquisition Corp

HCIIW Hudson Executive Investment Equity II Warrant Exp 31 Jan 2027 *W EXP 01/31/2027

MEDS TRxADE Health Inc

HCICW Hennessy Capital Investment V Equity Warrant Exp 15 Jan 2025 *W EXP 01/15/2025

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Company profile

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

DexCom Inc. Stock Underperforms Wednesday When Compared To Competitors

4:50 pm ET January 5, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of DexCom Inc. (DXCM) shed 4.77% to $487.81 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.94% to 4,700.58 and Dow Jones Industrial Average falling 1.07% to 36,407.11. This was the stock's fourth consecutive day of losses. DexCom Inc. closed $171.64 below its 52-week high ($659.45), which the company achieved on November 18th.

The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 0.67% to $172.22, Abbott Laboratories (ABT) fell 0.45% to $135.16, and Medtronic PLC (MDT) fell 0.36% to $106.01. Trading volume (703,802) remained 27,125 below its 50-day average volume of 730,927.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 5, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 05, 2022 16:50 ET (21:50 GMT)